NCT05852522 Molecularly Aided Stratification for Tumor Eradication Research
| NCT ID | NCT05852522 |
| Status | Recruiting |
| Phase | — |
| Sponsor | German Cancer Research Center |
| Condition | Rare Cancers |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2018-11-11 |
| Primary Completion | 2028-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2018-11-11 with a primary completion date of 2028-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
NCT/DKFZ/DKTK MASTER is a prospective, continuously recruiting, multicenter observational study for biology-guided stratification of adults with rare cancers, including rare subtypes of common entities, using comprehensive molecular profiling, and clinical decision-making in a multidisciplinary molecular tumor board.
Eligibility Criteria
Inclusion Criteria: Rare cancer (Incidence \<6/100,000 persons/year) or Rare subtype of a more common entity (case-by-case decision; example: pancreatic ductal adenocarcinoma without KRAS mutation) Metastatic and/or locally advanced cancer with no curative therapy option and indication for systemic therapy Exclusion Criteria: Severe neurological or psychiatric disorder interfering with the ability to give oral and written informed consent
Contact & Investigator
Stefan Fröhling, M.D.
PRINCIPAL INVESTIGATOR
German Cancer Research Center
Frequently Asked Questions
Who can join the NCT05852522 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rare Cancers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05852522 currently recruiting?
Yes, NCT05852522 is actively recruiting participants. Contact the research team at richard.schlenk@nct-heidelberg.de for enrollment information.
Where is the NCT05852522 trial being conducted?
This trial is being conducted at Heidelberg, Germany.
Who is sponsoring the NCT05852522 clinical trial?
NCT05852522 is sponsored by German Cancer Research Center. The principal investigator is Stefan Fröhling, M.D. at German Cancer Research Center. The trial plans to enroll 10,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.